Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-03-20
2007-03-20
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013800, C530S326000, C530S327000
Reexamination Certificate
active
11178316
ABSTRACT:
Method and peptide for regulating cellular activity includes a panel of synthesized peptides that have biological effects on inhibiting or enhancing cellular activity. Selected peptides can be used as therapy to reduce and/or inhibit, or initiate and/or enhance, an inflammatory response in a subject.
REFERENCES:
patent: 2005/0244430 (2005-11-01), O'Neill et al.
Bowie, et al., PNAS, 2000, 97, 10162-10167.
Wender, et al., PNAS, 2000, 97, 13003-13008.
D. Voet and J.G. Voet. Biochemistry, 2nd Edition.(1995), pp. 235-241.
McCoy. S.L. et al.,Identification of a Peptide Derived from Vaccinia Virus A52R Protein That Inhibits Cytokine Secretion in Response to TLR-Dependent Signaling and Reduces In Vivo Bacteria-Induced Inflammation. The Journal of Immunology, 2005, 174:3006-3014.
Takeda, K., and S. Akira. 2004. TLR signaling pathways.Seminars in Immunology 16:3-9.
Schnare M., G. M. Barton, A. C. Holt, K. Takeda, S. Akira, and R. Medzhitov. 2001. Toll-like receptor control activation of adaptive immune responses.Nat. Immuno. 2:947-950.
Granucci, F., C. Vizzardelli, N. Pavelka, S. Feau, M. Persico, E. Virzi, M. Rescigno, G. Moro, and P. Ricciardi-Castagnoli. 2001. Inducible II-2 production by dendritic cells revealed by global gene expression analysis.Nat. Immunol. 2:882-888.
Krieg, A. M. 2002. CpG motifs in bacterial DNA and their immune effects.Ann. Rev. Immunol. 20:709-760.
Trinchieri, G. 1998. Interleukin-12: a cytokine at the interface of inflammation and immunity.Adv. Immunol. 70:83-243.
Ozato, K., H. Tsujimura, and T Tamura. 2002. Toll-like receptor signaling and regulation of cytokine gene expression in the immune system.BioTechniquesOct. Suppl:66-75.
Yi, A. K., J. G. Yoon, S. C. Hong, B. K. English, and A. M. Krieg. 2002. Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response.J. Immunol. 168:4711-4720.
Fan, J. and A. B. Malik. 2003. Toll-like receptor-4(TLR4) signaling augments chemokine-induced neutrophil migration by modulating cell surface expression of chemokine receptors.Nat. Med. 9:315-321.
McCoy, S. L., S. E. Kurtz, F. A. Hausman, S. R. Trune, R. M. Bennett, and S. H. Hefeneider. 2004. Activation of RAW264.7 macrophages by bacterial DNA and lipopolysaccharide increases cell surface DNA binding and internalization.J. Biol. Chem. 279:17217-17223.
Hoshino, K., O. Takeuchi, T. Kawai, H. Sanjo, T. Ogawa, Y. Takeda, K. Takeda, and S. Akira. 1999. Cutting Edge: Tool-like receptor 4(TLR4)-deficient mice are hyproresponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product.J. Immunol. 162:3749-3752.
Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumo, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Toll-like receptor recognizes bacterial DNA.Nature 408:740-745.
Hayashi, F., K. D. Smith, A. Ozinsky, T. R. Hawn, E. C. Yi, D. R. Goodlett, J. K. Eng, S. Akira, D, M. Underhill, and A. Aderem. 2001. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5.Nature 410:1099-1103.
Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like receptors.Ann. Rev. Immunol. 21:335-378.
Akira, S. 2003. Mammalian Toll-like receptors.Curr. Opin. Immunol. 15:5-11.
Bowie, A., E. Kiss-Toth, J. A. Symons, G. L. Smith, S. K. Dower, and L. A. J. O'Neill. 2000. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling.Proc. Natl. Acad. Sci. U.S.A. 97:10162-10167.
O'Neill L. 2000. The Toll/interleukin-1 receptor domain: a molecular switch for inflammation and host defence.Biochem. Soc. Trans. 28:557-563.
Bellows, C. F., R. F. Garry, and B. M. Jaffe. 2003. Vaccinia virus-induced inhibition of nitric oxide production.J. Surg. Res. 111:127-135.
Harte, M. T., I. R. Haga, G. Maloney, P. Gray, P. C. Reading, N. W. Bartlett, G. L. Smith, A. Bowie, and L. A. J. O'Neill. 2003. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense.J. Exp. Med. 197:343-351.
Yi, A. K., and A. M. Krieg. 1998. Cutting Edge: Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA.J. Immunol. 161:4493-4497.
Wender, P. A., D. J. Mitchell, K. Pattabiraman, E. T. Pelkey, and L. Steinman. 2000. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters.Proc. Natl. Acad. Sci. U.S.A. 97:13003-13008.
Barzilai A., B. Dekel, R. Dagan, and E. Leibovitz. 2000. Middle ear effusion II-6 concentration in bacterial and non-bacterial acute otitis media.Acta Paediatr 89:1068-1071.
Takeda, K. and S. Akira. 2004. TLR signaling pathways.Semin. Immunol. 16:3-9.
Janssens, S., and R. Beyaert. 2003. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members.Mol. Cell 11:293-302.
Daun, J. M., and M. J. Fenton. 2000. Interleukin-1/Toll receptor family members: receptor structure and signal transduction pathways.J. Interferon Cytokine Res. 20:843-855.
Barton, G. M., and R. Medzhitov. 2003. Linking Toll-like receptors to IFN-α/β expression.Nat. Immunol. 4:432-433.
Karasen R. M., Y. Sutbeyaz, B. Aktan, H. Ozdemir, and C. Gundogu. 2000. Effect of web 2170 BS, platelet activating factor receptor inhibitor, in the guinea pig model of middle ear inflammation.Ann Otol Rhinol Laryngol 109:549-553.
Daly, K. A., L. L. Hunter, and G. S Giebink. 1999. Chronic Otitis Media with Effusion.Pediatrics in Review 20:85-93.
Kubba H., J. P. Pearson, and J. P. Birchall. 2000. The aetiology of otitis media with effusion: a review.Clin Otolaryngol 25:181-194.
O'Neill, L. A. J. 2003. Therapeutic targeting of Toll-like receptors for inflammatory and infectuous diseases.Curr. Opin. Pharm. 3:396-403.
Zuany-Amorim, C., J. Hastewell, and C. Walker. 2002. Toll-like receptors as potential therapeutic targets for multiple diseases.Nat. Rev. Drug Discov. 1:797-807.
Ikezoe, T., Y. Yang, D. Heber, H. Taguchi, and H. P. Koeffler. 2003. PC-SPES: A potent inhibitor of nuclear factor-κB rescues mice from lipopolysaccharide-induced septic shock.Mol. Pharmacol. 64:1521-1529.
Delgado, M., C. Abad, C. Martinez, M. G. Juarranz, J. Leceta, D. Ganea, and R. P. Gomariz. 2003. PACAP in immunity and inflammation.Ann. N. Y. Acad. Sci. 992:141-157.
Basu, S., and M. J. Fenton. 2004. Toll-like receptors: function and roles in lung disease.Am. J. Physiol. Lung Cell Mol. Physiol. 286:L887-892.
Kopp, E., and S. Ghosh. 1994, Inhibition of NF-kappa B by sodium salicylate and aspirin.Science 265:956-959.
Almawi, W. Y., and O. K. Melemedjian. 2002. Negative regulation of nuclear factor-kappaB activation and function by glucocorticoids.J. Mol. Endocrinol. 28:69-78.
Andreakos, E. T., B. M. Foxwell, F. M. Brennan, R. N. Maini, and M. Feldmann. 2002. Cytokines and anti-cytokine biologicals in autoimmunity: present and future.Cytokines Growth Factor Rev. 13:299-313.
Meng, G., M. Rutz, M. Schiemann, J. Metzger, A. Grabiec, R. Schwandner, P. B. Luppa, F. Ebel, D. H. Busch, S. Bauer, H. Wagner, and C. J. Kirschning. 2004. Antagonistic antibody prevents Toll-like receptor 2-driven lethal shock-like syndromes.J. Clin. Invest. 113:1473-1481.
Sweet, M. J., B. P. Leung, D. Kang, M. Sogaard, K. Schulz, V. Trajkovic, C. C. Campbell, D. Xu, and F. Y. Liew. 2001. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression.J. Immunol. 166:6633-6639.
Brint, E. K., D. Xu, H. Liu, A. Dunne, A. N. McKenzie, L. A. O'Neill, and F. Y. Liew. 2004. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance.Nat. Immunol. 5:373-379.
Chuang, T. H., and R. J. Ulevitch. 2004. Triad3A, and E3 ubiquitin-protein ligase regulating Toll-like receptors.Nat. Immunol. 5:495-502.
Bartfai, T., M. M. Behrens, S. Gaidarova, J. Pemberton, A. Shivanyuk, and J. Rebek, Jr. 2003. A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses.Proc. Na
Hefeneider Steven H.
McCoy Sharon L.
Dinesh Agarwal, P.C.
Gudibande Satyanarayana R.
Gupta Anish
Oregon Health & Science University
U.S. Department of Veterans Affairs
LandOfFree
Method and peptide for regulating cellular activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and peptide for regulating cellular activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and peptide for regulating cellular activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3799891